Terms: = Breast cancer AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300 AND Clinical Outcome
5 results:
1. Oncogenic ep300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
[TBL] [Abstract] [Full Text] [Related]
2. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract] [Full Text] [Related]
3. Complex formation and function of estrogen receptor α in transcription requires RIP140.
Rosell M; Nevedomskaya E; Stelloo S; Nautiyal J; Poliandri A; Steel JH; Wessels LF; Carroll JS; Parker MG; Zwart W
Cancer Res; 2014 Oct; 74(19):5469-79. PubMed ID: 25145671
[TBL] [Abstract] [Full Text] [Related]
4. Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.
Zwart W; Theodorou V; Kok M; Canisius S; Linn S; Carroll JS
EMBO J; 2011 Oct; 30(23):4764-76. PubMed ID: 22002538
[TBL] [Abstract] [Full Text] [Related]
5. Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression.
Hyseni A; van der Groep P; van der Wall E; van Diest PJ
Cell Oncol (Dordr); 2011 Dec; 34(6):565-70. PubMed ID: 21732131
[TBL] [Abstract] [Full Text] [Related]
